Delivery Order SPE2DB22D2206-SPE2DB25FHW80
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30 units, with a contract ceiling value of $7,043.20 and an ultimate completion date of November 14, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count packaging) with a contract value of $3,436.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 tablets, with a ceiling value of $20,173.94. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is being performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, and is scheduled for completion by August 8, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $4,885.54. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is scheduled for completion by August 20, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count) valued at $6,599.70. This is a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30, with a ceiling value of $23,438.54. This is a firm fixed price delivery order with no set-aside designation, completed through open competition. The order is scheduled for ultimate completion by September 2, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a $18,664.07 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count units) with a completion date of September 11, 2025. This competitive award, issued as a firm fixed-price delivery order with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with the agency. The pharmaceutical product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $1,961.44. This firm fixed price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count) with a ceiling value of $37,883.29. This competitively awarded, firm fixed-price delivery order is set to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating the award was made through...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHW80Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count) with a contract value of $8,069.34. This firm fixed-price delivery order, which must be completed by July 15, 2025, represents a single-award transaction with no set-aside designation, indicating it was awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of generic and brand-name medications, vaccines, and medical supplies to support military and veteran healthcare systems. The Ondansetron HCl delivery fulfills anti-nausea medication requirements for federal medical supply chains, demonstrating the company's ongoing role in supporting military healthcare operations across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 7/14/25 |